Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Hepatitis B Vaccine with SII Bulk vs Bio Farma Vaccine in Indonesia
NCT03919578Phase 3Completed
- Sponsor
- Bio Farma
- Start
- Sep 2019
- Primary completion
- Jan 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant hepatitis B vaccine Bio Farma in hepatitis B (HBV) (4 arms), sponsored by Bio Farma. Primary endpoint: Percentage of subjects with increasing antibody titer >= 4 times. Started Sep 2019; status: completed.
02
Drugs
recombinant hepatitis B vaccine Bio Farma
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03919578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919578.